Virios Therapeutics, LLC VIRI · Stock Open Virios Therapeutics, LLC in new tab
Analyst price targets
Recent rating changes, newest first
Virios Therapeutics, LLC Analysis (VIRI)
Is Virios Therapeutics, LLC a good investment? Virios Therapeutics, LLC (VIRI) is currently trading at 0.1550 USD. Market analysts have a consensus price target of 3.00 USD. This suggests a potential upside from current levels.
Investor FAQ
Does Virios Therapeutics, LLC pay a dividend?
No, it does not currently pay a dividend.
What asset class is Virios Therapeutics, LLC?
Virios Therapeutics, LLC is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
Company Profile
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
| Split Date | Split Ratio to 1 |
|---|---|
| Oct. 9, 2024 | 1:25 |
Community Discussion